Patients with early to locally advanced NSCLC, including stage IA and stage IIIA
Care Setting
Surgical oncology and thoracic surgery clinical practice
Key Highlights
Sublobar resection offers significantly better postoperative quality of life compared to lobectomy.
Postoperative radiotherapy (PORT) may improve overall survival in resectable pN2 stage IIIA NSCLC, especially with multiple lymph node metastases.
Advanced lymph node metrics (LODDS, NLN, NPLN, LNR) provide prognostic value in NSCLC survival prediction.
Guideline-Based Recommendations
Diagnosis
Use preoperative CT-based radiomic models combined with clinical features to non-invasively predict spread through air spaces (STAS) in stage IA lung adenocarcinoma.
Incorporate lymph node assessment methods such as positive lymph node count, lymph node ratio, and log odds ratio for positive lymph nodes for prognosis.
Management
Consider sublobar resection as a surgical option to improve postoperative quality of life in appropriate NSCLC patients.
Apply postoperative radiotherapy in resectable pN2 stage IIIA NSCLC patients with extensive lymph node metastasis to potentially improve survival.
Monitoring & Follow-up
Monitor lymph node counts and ratios postoperatively as independent prognostic indicators to guide follow-up and adjuvant therapy decisions.
Risks
Further prospective studies are needed to validate prognostic models and the survival benefit of PORT in extensive lymph node metastasis.
Patient & Prescribing Data
NSCLC patients undergoing surgical resection including sublobar resection and lobectomy
Sublobar resection improves postoperative quality of life; PORT may enhance survival in select stage IIIA patients; lymph node metrics assist in prognosis and treatment planning.
Clinical Best Practices
Utilize advanced lymph node staging systems (LODDS, NLN, NPLN, LNR) for accurate prognostication in NSCLC.
Incorporate AI-driven radiomic analysis of preoperative CT scans to identify STAS and inform surgical planning.
Tailor postoperative radiotherapy decisions based on lymph node metastasis burden in stage IIIA NSCLC.
